GSTU10 Antibody

What is GSTU10 Antibody and how does it relate to the broader GST family?

GSTU10 antibody is a specialized immunoglobulin that recognizes and binds to Glutathione S-transferase U10, a member of the tau class of GST enzymes. GSTs comprise a diverse family of detoxification enzymes that catalyze the conjugation of glutathione to various electrophilic compounds . The tau class (GSTU) represents plant-specific GSTs, with GSTU10 being particularly important in plant stress responses and xenobiotic metabolism.

The broader GST family includes multiple classes (alpha, mu, pi, omega, theta, zeta, and others) with varied tissue distribution and substrate specificity. These enzymes share a common ability to conjugate the tripeptide glutathione to electrophilic centers on various molecules, thereby increasing their water solubility and facilitating their elimination from cells .

What are the most common research applications for GST antibodies?

GST antibodies find application across numerous experimental techniques and research areas:

These applications derive from the high specificity of GST antibodies for their target proteins, enabling precise detection and quantification in complex biological samples .

What different formats and conjugates are available for GST antibodies?

GST antibodies are available in various formats to suit different experimental needs:

For example, the GST monoclonal antibody [2H3-D10]:HRP represents an HRP-conjugated format specifically designed for Western blotting applications, purified by affinity chromatography on Protein G from tissue culture supernatant .

How should researchers optimize GST antibody protocols for Western blotting?

Optimizing Western blot protocols for GST antibodies requires attention to several critical parameters:

• Sample Preparation:

  • For GST-fusion proteins: Include reducing agents (DTT or β-mercaptoethanol) to disrupt potential disulfide bonds

  • Avoid excessive heating (>70°C) which may cause aggregation of GST proteins

  • Include protease inhibitors to prevent degradation

• Gel Selection and Transfer:

  • For GST (~26 kDa) and smaller GST-fusion proteins: 12-15% polyacrylamide gels

  • For larger GST-fusion proteins: 8-10% gels

  • Semi-dry transfer: 15-25V for 30-45 minutes

  • Wet transfer: 100V for 60-90 minutes in 10-20% methanol buffer

• Antibody Incubation:

  • Primary antibody (e.g., Mouse Anti-GST [2H3-D10]): Begin with 1:1000 dilution and optimize as needed

  • Extended incubation at 4°C overnight often yields better results than short room temperature incubations

  • For HRP-conjugated antibodies, shorter incubation times (1-2 hours) at room temperature are typically sufficient

• Detection Optimization:

  • For chemiluminescent detection with HRP-conjugated antibodies, exposure times typically range from 30 seconds to 5 minutes

  • Signal enhancement systems may help with low-abundance proteins

Validation should include appropriate controls such as recombinant GST protein (positive control) and lysates from cells not expressing GST or GST-fusion proteins (negative control).

What are the critical factors for successful immunoprecipitation using GST antibodies?

Successful immunoprecipitation (IP) with GST antibodies depends on several key considerations:

• Lysis Buffer Composition:

  • Use mild, non-denaturing buffers (e.g., RIPA or NP-40-based buffers)

  • Include protease inhibitors and phosphatase inhibitors if studying phosphorylation states

  • Typical composition: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate

• Pre-clearing Strategy:

  • Pre-clear lysates with protein G beads (for mouse antibodies) or protein A beads (for rabbit antibodies)

  • Incubate for 30-60 minutes at 4°C to reduce non-specific binding

• Antibody Binding Conditions:

  • Use 2-5 μg of antibody per 500 μg of total protein

  • Incubate overnight at 4°C with gentle rotation

  • For crosslinking to beads, use disuccinimidyl suberate (DSS) or dimethyl pimelimidate (DMP)

• Washing Protocol Stringency:

  • Sequential washes with decreasing salt concentration

  • Typically 3-5 washes with cold IP buffer

  • Final wash with PBS or TBS to remove detergents

• Elution Methods:

  • Gentle: Non-reducing SDS sample buffer at room temperature

  • Denaturing: Boiling in reducing SDS sample buffer

  • Native: Competitive elution with excess glutathione (for GST-tagged proteins)

For co-immunoprecipitation studies investigating protein-protein interactions with GST-fusion proteins, maintaining native protein conformations is critical, necessitating careful buffer composition and minimal detergent use.

How should researchers approach GST antibody use in immunofluorescence studies?

Effective immunofluorescence (IF) with GST antibodies requires attention to fixation, permeabilization, and detection parameters:

• Fixation Protocol Selection:

  • Paraformaldehyde (4%) for 12-15 minutes preserves most epitopes and cellular structures

  • Methanol fixation (ice-cold, 10 minutes) can improve access to some intracellular epitopes but may disrupt certain membrane proteins

• Permeabilization Optimization:

  • Triton X-100 (0.5%) for 5 minutes permeabilizes membranes effectively

  • Saponin (0.1-0.2%) provides gentler permeabilization for certain applications

  • Digitonin (0.01-0.1%) for selective plasma membrane permeabilization

• Blocking Conditions:

  • 5-10% normal serum (from secondary antibody host species)

  • Addition of 0.1-0.3% Triton X-100 to blocking buffer improves penetration

• Antibody Incubation Parameters:

  • Primary antibody dilutions typically range from 1:100 to 1:500

  • Incubation at 4°C overnight often yields better signal-to-noise ratios

  • For direct conjugates (e.g., fluorophore-labeled GST antibodies), shorter incubations (1-2 hours) at room temperature

• Detection Strategies:

  • Fluorophore-conjugated secondary antibodies (e.g., Northern-Lights™ 557-conjugated Anti-Sheep IgG)

  • Counterstain nuclei with DAPI (1 μg/ml, 5 minutes)

  • Mount in anti-fade mounting medium to preserve fluorescence

For example, Human GSTP1 antibody successfully detected the protein in HeLa cells using 10 μg/ml concentration with a 3-hour room temperature incubation, followed by detection with Northern-Lights™ 557-conjugated secondary antibody and DAPI counterstaining .

How can researchers address cross-reactivity issues with GST antibodies?

Cross-reactivity represents a significant challenge when working with GST antibodies due to the high sequence homology between GST family members. Researchers can employ several strategies to address this issue:

• Epitope Mapping and Antibody Selection:

  • Choose antibodies raised against unique regions of the target GST

  • Monoclonal antibodies like 2H3-D10 offer higher specificity than polyclonals

  • Review epitope information provided by manufacturers

• Validation in Knockout/Knockdown Systems:

  • Test antibody specificity in systems where the target GST is genetically depleted

  • Compare signal in wild-type vs. knockout tissues or cells

  • Employ siRNA knockdown to create transient depletion controls

• Peptide Competition Assays:

  • Pre-incubate antibody with excess target peptide/protein

  • True signal should be significantly reduced or eliminated

  • Use closely related GST family members to test cross-reactivity

• Additional Controls and Countervalidation:

  • Include recombinant GST proteins from different classes

  • Test specificity across species (e.g., human vs. mouse vs. rat GSTs)

  • Use multiple antibodies targeting different epitopes of the same protein

Careful antibody selection and rigorous validation are crucial to minimize cross-reactivity issues when studying specific GST family members.

What quality control measures ensure GST antibody specificity and reproducibility?

Ensuring antibody specificity and experimental reproducibility requires comprehensive quality control measures:

• Antibody Production Quality Controls:

  • Immunogen purity verification (>95% purity by SDS-PAGE)

  • Clone stability testing for monoclonal antibodies

  • Lot-to-lot consistency validation by ELISA and Western blot

• Specificity Testing Methods:

  • Western blot against recombinant GST proteins and cellular lysates

  • Dot blot analysis with purified recombinant protein

  • Testing across multiple applications (WB, IP, ICC) to confirm consistent specificity

• Validation in Multiple Cell Types/Tissues:

  • Testing in cells with known expression levels (e.g., HeLa cells for GSTP1)

  • Comparison of staining patterns with published literature

  • Correlation with mRNA expression data from transcriptomic databases

• Documentation Standards:

  • Complete antibody datasheet information including host, clone, isotype

  • Detailed experimental protocols with critical parameters

  • Appropriate citation of antibody source and validation methods

• Analytical Validation:

  • Linear dynamic range determination

  • Limit of detection and limit of quantitation assessment

  • Intra-assay and inter-assay coefficient of variation calculation

For example, the GST Monoclonal Antibody [2H3-D10]:HRP is purified by affinity chromatography and validated specifically for Western blot applications, with detailed information provided regarding host species (mouse), isotype (IgG1), and fusion partners (X63-Ag8.653) .

How can researchers detect anti-GST autoantibodies in clinical samples?

The detection of anti-GST autoantibodies in clinical samples, such as those against GSTO1-1 in inflammatory conditions, requires specialized methodologies:

• ELISA Development and Optimization:

  • Immobilize purified recombinant GST protein (e.g., GSTO1-1) on microplates

  • Block with appropriate buffers (typically 5% BSA or milk in PBS)

  • Incubate with diluted patient sera (typically 1:100 to 1:500)

  • Detect bound antibodies with HRP-conjugated anti-human IgG antibodies

  • Quantify using a calibration curve with known antibody standards

• Dot-Blot Analysis Protocol:

  • Apply small volumes (3 μl) of purified recombinant GST protein to nitrocellulose membrane

  • Block with 5% dry milk in TBS-T buffer

  • Incubate with diluted sera (1:100) for 1 hour at room temperature

  • Detect using HRP-conjugated anti-human IgG antibody

  • Analyze using ECL detection systems and imaging equipment

• Immunocytochemistry Confirmation:

  • Use human cell lines expressing the target GST (e.g., HepG2, HeLa)

  • Fix and permeabilize cells appropriately

  • Incubate with patient sera followed by fluorescent-labeled secondary antibodies

  • Compare staining patterns with positive and negative controls

• Result Interpretation Guidelines:

  • Establish cutoff values based on healthy control populations

  • Analyze positivity rates in different disease states

  • Correlate antibody levels with clinical parameters and disease severity

Research has shown that anti-GSTO1-1 antibodies can be detected in various inflammatory conditions including COVID-19, rheumatoid arthritis, and trichinellosis, with positivity rates of 35%, 46%, and 60% respectively, compared to approximately 40% of healthy subjects with very low or undetectable levels .

How are GST antibodies utilized in cancer research?

GST antibodies have become increasingly important tools in cancer research, with applications spanning from biomarker discovery to therapeutic development:

• Biomarker Identification and Validation:

  • Detection of overexpressed GST enzymes in various cancers

  • GSTP1 is frequently overexpressed in many cancers and can be detected using specific antibodies like the Human GSTP1 Antibody

  • GSTO1-1 autoantibodies were initially proposed as potential biomarkers for esophageal squamous cell carcinoma with 44.8% detection frequency in cancer patients versus 6.7% in normal controls

• Drug Resistance Mechanism Studies:

  • Examination of GST expression levels in chemotherapy-resistant tumors

  • Correlation of GST activity with response to specific therapeutic agents

  • Development of inhibitors targeting specific GST isoforms

• Cellular Localization Analysis:

  • Immunofluorescence studies to track GST distribution in cancer cells

  • Investigation of nuclear vs. cytoplasmic localization and its significance

  • Correlation of localization patterns with malignant phenotypes

• Antibody-Based Therapeutic Approaches:

  • Development of antibodies targeting cancer-specific GST epitopes

  • Antibody-drug conjugates (ADCs) targeting GST-overexpressing tumors

  • Similar to other tumor-targeting approaches, such as antibodies stimulating natural killer cells for immunotherapy-resistant cancers

Recent research has challenged the specificity of some GST autoantibodies as cancer biomarkers. For instance, anti-GSTO1-1 antibodies were found in various inflammatory conditions, suggesting they may be general markers of tissue damage/inflammation rather than specific tumor-associated biomarkers .

What role do GST antibodies play in immunological and inflammatory disease research?

GST antibodies have important applications in studying immunological and inflammatory processes:

• Autoantibody Detection in Inflammatory Conditions:

  • Anti-GSTO1-1 antibodies have been detected in patients with:

    • COVID-19 (acute inflammation)

    • Rheumatoid arthritis (chronic autoimmune inflammation)

    • Trichinellosis (parasite-induced inflammation)

• Correlation with Disease Biomarkers:

  • Anti-GSTO1-1 antibody levels correlate with inflammatory markers:

    • C-reactive protein (CRP) levels in rheumatoid arthritis patients

    • Lactate dehydrogenase (LDH) levels in COVID-19 patients

  • These correlations suggest antibody production may result from tissue damage and release of intracellular GST

• Mechanistic Studies of Inflammatory Processes:

  • Investigation of GST involvement in modulating:

    • Toll-like receptor 4-mediated pathways

    • NLRP3 inflammasome activation

    • Production of proinflammatory cytokines

• Tissue Damage Assessment:

  • Anti-GST antibodies may serve as indicators of cellular damage

  • Abnormal expression and release of GST enzymes upon cellular damage could trigger autoantibody production

  • Potential use as general markers of tissue damage/inflammation

Research suggests that the presence of anti-GSTO1-1 antibodies in different inflammatory conditions indicates their potential role as markers of tissue damage rather than disease-specific biomarkers. This understanding helps researchers better interpret the significance of these antibodies in various pathological states .

What advances in GST antibody engineering are driving new research applications?

Recent advances in antibody engineering have expanded the utility of GST antibodies in research:

• Novel Conjugation Technologies:

  • Site-specific conjugation methods preserve antibody function

  • Lightning-Link® technology enables rapid conjugation of enzymes like HRP to GST antibodies

  • Photochemical conjugation approaches for attaching fluorophores at precise locations

• Fragment-Based Antibody Derivatives:

  • F(ab) and F(ab')₂ fragments for reduced background in sensitive applications

  • Single-chain variable fragments (scFvs) for improved tissue penetration

  • Nanobodies derived from camelid antibodies for accessing sterically restricted epitopes

• Bispecific Antibody Platforms:

  • Dual-targeting antibodies that recognize GST plus a second protein of interest

  • Applications in pull-down assays to study protein complexes

  • Potential therapeutic applications targeting GST-overexpressing cells

• Recombinant Antibody Production:

  • Humanized anti-GST antibodies for reduced immunogenicity in therapeutic applications

  • Antibody library screening for identifying high-affinity GST-binding variants

  • CRISPR-engineered cell lines expressing recombinant antibodies with defined properties

• Therapeutic Antibody Development Strategies:

  • Similar to Regeneron's Factor XI antibodies (REGN7508 and REGN9933) which target different domains (catalytic and A2 domains)

  • Domain-specific targeting of GST enzymes could enable selective modulation of specific functions

These advances are enabling more precise targeting, improved detection sensitivity, and novel therapeutic applications of GST antibodies across multiple research domains, from basic science to clinical translation.

What emerging technologies will impact GST antibody applications?

The field of GST antibody research continues to evolve with several promising technological directions:

• Single-cell Antibody Analytics:

  • Integration with single-cell proteomics for analyzing GST expression at individual cell resolution

  • Spatial transcriptomics combined with GST antibody staining to correlate protein expression with tissue architecture

  • Microfluidic platforms for high-throughput GST antibody screening in rare cell populations

• AI-Driven Epitope Prediction and Antibody Design:

  • Computational approaches to identify optimal GST epitopes with minimal cross-reactivity

  • Machine learning algorithms to predict antibody performance across applications

  • In silico optimization of antibody properties before experimental validation

• Multiplexed Detection Systems:

  • Simultaneous detection of multiple GST family members in single samples

  • Antibody panels for comprehensive GST profiling in disease states

  • Integration with mass cytometry for highly multiparametric analysis

• Therapeutic Applications in Precision Medicine:

  • Similar to approaches like the antibody designed to fight immunotherapy-resistant cancers by stimulating natural killer cells

  • Patient stratification based on GST expression profiles

  • Combination therapies targeting GST-mediated drug resistance mechanisms

As research continues to unveil the complex roles of GST enzymes in normal physiology and disease states, antibodies targeting these proteins will remain essential tools for both basic research and clinical applications, with continuous refinement of specificity, sensitivity, and versatility.